Brief Reports
Copyright ©The Author(s) 2004.
World J Gastroenterol. Feb 1, 2004; 10(3): 427-432
Published online Feb 1, 2004. doi: 10.3748/wjg.v10.i3.427
Table 2 Comparison of serum CA19-9 and CEA levels in patients with cholangiocarcinoma and benign biliary diseases
CA19-9CA19-9CEACA19-9 or CEACA19-9 and CEA
Sensitivity(true positive)*65.71%(23/35)77.14%(27/35)a68.57%(24/35)91.43%(32/35)62.86%(22/35)
Specificity(true negative)**88.04%(81/92)84.78%(78/92)81.52%(75/92)76.09%(70/92)86.96%(80/92)
Positive predictive value67.65%(23/34)65.85%(27/41)58.54%(24/41)59.26%(32/54)64.71%(22/34)
Negative predictive value87.10%(81/93)90.70%(78/86)87.21%(75/86)95.89%(70/73)88.89%(80/90)
Accuracy81.89%(104/127)82.68%(105/127)77.95%(99/127)80.31%(102/127)80.31%(102/127)
False positive rate11.98%(11/92)15.22%(14/92)18.48%(17/92)23.91%(22/92)13.04%(12/92)